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October 5, 2010:1263–6ver a 4- to 17-year period, 114 athletes who had participated in
t least 2, and up to 5, consecutive Olympic Games. These athletes
epresented an unique and selected population exposed to extraor-
inarily intense and prolonged athletic conditioning and, there-
ore, were a model to study the question of whether nondiseased
earts with physiologic hypertrophy can be affected adversely (or
ven pathologically) by high-level intensive training over particu-
arly long periods of time.
We have been criticized by Dr. La Gerche and colleagues for
ur focus on the left ventricle in these highly trained athletes (i.e.,
ather than the right ventricle). However, this strategy was based
n certain realistic considerations. First, previous investigations
ave raised concern and/or produced evidence for left ventricular
ysfunction in trained athletes (2,3). Second, with echocardiogra-
hy, we were able to reliably assess changes in left ventricular
orphology and function, which is not easily achieved for the right
entricle with this imaging modality. More precise observations
oncerning right ventricular structure and function in trained
thletes will likely come from studies employing cardiovascular
agnetic resonance imaging.
In summary, our results demonstrate that exercise conditioning
s not responsible itself for left ventricular dysfunction or abnormal
ardiac morphologic changes in long-term Olympic athletes and
onfirms the benign nature of physiologic athlete’s heart, even
nder extreme conditions over extended periods of time. There-
ore, left ventricular dysfunction in trained athletes should raise the
linical suspicion of an underlying pathologic condition.
Antonio Pelliccia, MD
arry J. Maron, MD
Institute of Sports Medicine and Science
argo Piero Gabrielli, 1
0197 Rome
taly
-mail: antonio.pelliccia@coni.it
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rug-Eluting Stents
or Critical Limb Ischemia
eiring et al. (1) presented very compelling data regarding the use
f small diameter (coronary) drug-eluting stents (DES) for the
reatment of infrapopliteal lesions in patients with critical limb
schemia. Their long-term outcomes in regard to patency and limb
alvage suggest that this may become the preferred method of
reatment for these often-challenging patients.The investigators are correct in noting that their data raise
everal important questions that should be addressed in an
ndustry-supported randomized prospective trial to better define
he role of DES for peripheral arterial disease with the goal of
btaining additional U.S. Food and Drug Administration indica-
ions for the use of such stents. These issues can be summarized as
ollows.
First, the biological mechanisms by which DES in the tibial
rteries are able to limit restenosis, whereas in the larger-caliber
uperior femoral artery most DES trials have been less promising,
eeds to be better studied. Second, in this patient population,
ltimately clinical outcomes (limb salvage and the relief of rest
ain) and not long-term patency should be the goal. The classic
eaching that “less blood is required to heal tissue than to keep it
ealed” can be applied to the notion that restenosis in this setting
ay occur without clinical consequences. The relationship be-
ween angiographic patency rates and improved clinical outcomes
emains an unanswered question. Finally, the study by Feiring et
l. (1) is similar to nearly every published series of critical limb
schemia patients in regard to the extraordinarily high mortality
ates of this population. This particularly sick population requires
ggressive, multidisciplinary, secondary prevention strategies, and
ore comprehensive approaches to develop data and strategies to
ecrease this high mortality.
We thank Feiring et al. (1) for publishing this data. His efforts
nd treatment strategies have the potential to lead to more
omprehensive, larger-scale efforts to improve the care of this
opulation of ill patients.
Robert S. Dieter, MD, RVT
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eply
e appreciate the comments of Dr. Dieter and colleagues regard-
ng our paper (1) and thank them for the opportunity to expand on
heir insightful observations.
. Although the biologic effect of drug-eluting stents (DES) in
crural arteries needs further investigation, current data suggests
that below-the-knee arterial lesions respond to coronary DES
in a similar fashion. This is not surprising because these 2
arteries are similar in both dimensions and histology. However,
drawing parallels between self-expanding superficial femoral
artery (SFA) DES trials and crural DES implants is unwar-
ranted. The SFA has 4 times the cross-sectional atherosclerotic
burden compared to crural lesions. Additionally, SFA lesions
are far more diffuse and the dynamic stresses are more severe
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October 5, 2010:1263–6than for tibial arteries. Compared with coronary DES, self-
expanding struts are thicker, the drug-free interstices are wider,
and the dosimetry per volume of plaque is lower. Thus,
predicting the effectiveness of below-the-knee DES based on
previous SFA trials may be deceptive.
. Although limb salvage and relief of rest pain are the primary
goals of critical limb ischemia therapy, we propose that ex-
tended arterial patency is an additional end point that deserves
consideration. The mantra that “patency need only be main-
tained long enough to affect healing” is derived from observa-
tion that long-term bypass patency is suboptimal. Previous
studies (referenced in the PaRADISE [Preventing Amputa-
tions Using Drug Eluting Stents] trial), demonstrated excellent
short-term DES patency. Recently, Balzer et al. (2) reported
that 83% of Cypher stents (Cordis Corp., Bridgewater, New
Jersey) (n  341) were patent at 18 months. Whereas bypass
surgery demonstrates time-dependent decremental graft pa-
tency and limb salvage, data from the PaRADISE trial and
Balzer et al. (2) suggests that stent patency and limb salvage
remain nearly constant after the first 6 months. Thus, DES may
facilitate long-term patency translating into fewer repeat inter-
ventions and reduced health care costs.
. Reducing mortality in critical limb ischemia remains a signifi-
cant challenge. However, a DES-centered endovascular strat-
egy may offer significant improvement over current therapy.
The 1-year mortality in the PaRADISE trial was 11%. The
median age of death was 80 years (95% confidence interval: 74
to 86 years), which is comparable to expected actuarial survival.
In comparison, first-year mortality in the BASIL (Bypass
Versus Angioplasty in Severe Ischaemia of the Leg) trial (3) was
20%, and in the PREVENT III trial (4), mortality was 15%
even though patients were a mean of 7 years younger. We
postulate that PaRADISE’s apparent survival advantage is
related to reduction in deaths from surgery, amputation, proce-
dural complications, and more aggressive secondary prevention.
ontemporary evidence indicates that the time is right for an
ndustry-sponsored U.S. Food and Drug Administration indepen-
ent developmental evaluation designed to investigate the impact
f DES on limb salvage, cost-effectiveness, and quality of life in
atients with critical limb ischemia.
Andrew J. Feiring, MD
or the PaRADISE Authors
Cardiology
olumbia-St. Mary’s Medical Center
uite 600
ilwaukee, Wisconsin 53211-1643
-mail: afeiring@execpc.com
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ransradial Coronary Intervention
adiant or Brilliant?
e read with great interest the recently published review of Rao et
l. (1) regarding the clinical benefits of using the transradial
pproach for percutaneous coronary interventions (PCI). The
aper outstandingly demonstrates how deeply a technical modifi-
ation might influence our current clinical practice. Despite these
enefits, the paper attracts the reader’s attention to the low
doption rate of this technique that is primarily supplied by the
ears and thoughts from the learning curve of the undevoted
perators. In the current correspondence, we would like to extend
he Rao et al. (1) discussion with the findings of 2 recent
bservations.
Rao et al. (1) cited and discussed 2 comprehensive meta-
nalyses of randomized comparisons between the transradial PCI
nd transfemoral PCI approaches (2,3). Although these studies
emonstrated a significant reduction in bleeding- and access
ite-related complications, they failed to find a significant link
etween the frequency of adverse cardiovascular events or mortal-
ty. It should be noted that these analyses included studies
erformed predominantly in elective settings and thus the benefit
f the higher-risk patients may have been concealed by the
ow-risk cases that may have formed the majority. In a recent
eta-analysis of 12 studies involving 3,324 patients with ST-
egment elevation myocardial infarction, we demonstrated that
eyond the bleeding benefit, radial, when compared to transfemo-
al, approach reduced the risk of death, myocardial infarction,
rgent revascularization, or stroke by 44% (odds ratio [OR]: 0.56
95% confidence interval (CI): 0.39 to 0.79]; p  0.001) and
ortality by 46% (OR: 0.54 [95% CI: 0.33 to 0.86]; p 0.01) (4).
oreover, there were no differences in procedural times and in
ime to reperfusion between the 2 access routes. Fluoroscopic times
ere longer in cases of transradial PCI; however, there was
ignificant heterogeneity among studies in these parameters.
Another trial that might add important observations to this
opic is the RAPTOR (Radial Access versus conventional femoral
uncTure: Outcome and Resource effectiveness in a daily routine)
tudy (5). The RAPTOR study was a prospective, randomized,
ingle-center trial to compare radial versus femoral access in an
nselected population. The study has demonstrated that an im-
ediate, ad hoc switch to the transradial program is feasible for an
nterventional site with operators experienced in femoral access.
he trial showed that transradial PCI was not associated with
onger procedural or radiation times, nor with higher rates of
ccess site failures. Procedural and fluoroscopic times and radiation
oses were only greater in case of the diagnostic angiographies, but
ot for PCIs.
In conclusion, the use of transradial PCI is not only beneficial to
educe bleeding but also for ischemic complications and mortality
n high-risk patients undergoing coronary interventions. The
